Clinical Data

Studied Disease	Clinical Data	Conclusions
Acne	Acne vulgaris/Rosacea open-label retrospective, cohort study examining the efficacy of Acunol® when used alone or in combination with other oral or topical therapies.	Acunol® demonstrates significant improvement in 4 weeks when used alone or in combination oral or topical therapies. Percent of patients with at least moderate improvement as measured by a subjective patient assessment. % of Patients Improving: Using Acunol® Only: 95% Using Acunol® + 1 or more Topical Medications: 85% Using Acunol® + Low Dose Oral Antibiotic: 95% Using Acunol® + Low Dose Oral Antibiotic + 1 or more Topical Medications: 88%

Studied Disease	Clinical Data	Conclusions
Eczema/Atopic Dermatitis	Eczema/Atopic Dermatitis open-label retrospective, cohort Study examining the efficacy of Eczemol® when used alone or in Combination with other oral and/or topical therapies.	Eczemol® demonstrates significant improvement in 4 weeks when used alone or in combination oral or topical therapies. Percent of patients with at least moderate improvement as measured by a subjective patient assessment. % of Patients Improving: Using Eczemol® Only: 80% Using Eczemol® + 1 or more Topical Medications: 90% Using Eczemol® + Oral Medication + 1 or more Topical Medications: 90%
Eczema/Atopic Dermatitis	Effective Treatment of Eczema/Atopic Dermatitis using a low dose, oral medication in an open-label retrospective Cohort study.	The clearing of eczema to the patient’s satisfaction were 88%. When Eczemol® was used alone, 80% were improved. Where Eczemol® was used with topical treatments, the result was 90% Improvement.

Studied Disease	Clinical Data	Conclusions
Psoriasis	Psoriasis open-label retrospective, cohort study examining the efficacy of Psorizide®Forte when used in combination with other oral and/or topical therapies.	Psorizide®Forte demonstrates significant improvement in 4 weeks when used in combination oral or topical therapies – improving signs and symptoms in psoriasis patients. Reductions in: thickness of plaque, scaling, erythema. Relief of: pruritus, pain, discomfort. Percent of Patients with at least moderate improvement as measured by a subjective patient assessment. % of Patients Improving: Using Psorizide®Forte + 1 or more Topical Medications: 85% Using Psorizide®Forte + Oral Medication + 1 or more Topical Medications: 89%
Psoriasis	Improvement of Psoriasis Vulgaris with Oral Nickel Dibromide	During the 12 weeks of active treatment, patients in the high serum nickel subgroup improved significantly more than those in the low subgroup (self-assessment, clinical assessment, independent photographic assessment). When compared with the patients taking placebo, the High serum nickel subgroup improved significantly while the low serum nickel subgroup did not. We present this information suggesting a link of nickel and bromide pharmacological characteristics (and possibly pathophysiological features) with the psoriatic process. Further studies are needed to investigate not only the independent effects of treatment with nickel and bromide, but also the dose-response relationship of multiple-dose groups and the underlying mechanism of action.
Psoriasis	Elevated Serum Nickel Concentration in Psoriasis Vulgaris	There is a statistically significant difference between the mean serum nickel concentrations in patients with psoriasis and in control subjects. These higher nickel concentrations in the psoriatic group could point to a defective cellular transport mechanism or a defective nickel-dependent Metalloenzyme that may result in a compensatory increase in nickel Absorption/retention. This suggests that a biochemical defect in the in the psoriatic process could be related to nickel homeostasis or function in the body. These findings point the way to further studies.